Cleveland BioLabs, Inc. (CBLI)

diversified1 (60.09) Submitted: 10/29/2007 11:48:42 PM : Start Price: $12.60 CBLI Score: -44.18

Read the Bios of their researchers, you will be impressed. In this world the projects they are working on are timely and amazing.

sixfigsdn (54.10) Submitted: 9/18/2007 7:21:54 PM : Start Price: $12.00 CBLI Score: -43.02

Expecting 200M+ dod contract to develope ARS drug in October.

BigWhereItCounts (< 20) Submitted: 7/14/2007 8:22:56 PM : Start Price: $11.00 CBLI Score: +39.33

Way too high of price/sales and price/book

zaphelps (< 20) Submitted: 5/29/2007 11:11:28 AM : Start Price: $9.28 CBLI Score: -34.49

The company focuses on radiation drug discovery. The drugs they are working on target only cancer cells and don't harm normal tissues. Their inital target is to protect humans from radiation as a result of a terrorist attack or nuclear accident.

NetscribeServcs (< 20) Submitted: 3/21/2007 7:51:49 AM : Start Price: $8.90 CBLI Score: +38.72

Cleveland Biolabs (CBL) is a biotechnology research and development company, which develops drugs offering protection from radiation and cancer. CBL is engaged in the development of small molecule drugs and biologics focusing on two therapeutic directions, which includes development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (protectans), and development of anti-cancer drugs for regulating cell death (curaxins).

Financially company has been running in losses from past three-four years. For the nine months ended in 2006, company’s revenues increased 93% to $1.5 million predominantly driven by increase in government grants. But it had a net loss totaled of $4.3 million, which was owing to an increase in selling, general and administrative expenses. Also due to creating and improving the infrastructure of the company and higher research & development expenses incurred for internal projects.

CBL intends to respond to a Request for Proposal (RFP) recently issued by the Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures to treat gastrointestinal effects of acute radiation syndrome. More recently company completed a $30 million private placement. This will provide them with two years of working capital and enable them to fulfill the requirements of the DoD's RFP as well as move forward with the development of radiation protection, cancer treatment and stem cell proliferation. But the above would gain only in the long run.

Looking at all the above factors and consequently due to increasing expenses in research & development every year coupled with deteriorating financials, the scrip is expected to enter a bearish phase.

hyronx (< 20) Submitted: 2/27/2007 6:31:08 PM : Start Price: $9.47 CBLI Score: -42.08

This stock went way up since New Year 2007 and made up to 150%

obiwankenobe1250 (85.35) Submitted: 2/24/2007 8:51:34 AM : Start Price: $11.01 CBLI Score: -44.69

Just for the fun of it, let's see how this pick plays out. Bio medical, stem cell researcher, cutting edge company in a bleeding edge industry. This is a long shot and bound to take some hits in the near term but long term prognosis looks good enough for a CAPS pick. Thanks, pennysplants!

KatWoman50 (63.68) Submitted: 2/23/2007 2:32:08 PM : Start Price: $11.00 CBLI Score: -44.88

penny's recommendation. It seems that the feds would be interested in a

pennysplants (99.28) Submitted: 2/22/2007 12:32:31 PM : Start Price: $11.83 CBLI Score: -47.22

Just listened to live presentation at Roth Capital. These people are smart. They are very small, have the right business attitude, AND have some very exciting programs underway. They are not covered, but that may change shortly. While they are high-flying (price-wise) they took a pre-presentation haircut from their 52-week high. For purposes of CAPS, very worthwhile following this one closely.

ARBinEXILEman (50.73) Submitted: 2/21/2007 10:43:18 PM : Start Price: $13.52 CBLI Score: -51.08

buy buy buy